Metacrine, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MTCR research report →
Price Chart
About the company
Metacrine, Inc. , established in 2014 and operating from its headquarters in San Diego, California, is a clinical-stage biopharmaceutical company. The firm's core mission involves identifying and advancing novel therapies specifically designed for patients suffering from gastrointestinal disorders.
- CEO
- David M. Maggio
- IPO
- 2020
- Employees
- 10
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on MTCR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $0
- P/E
- -0.40
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.43
- EV/EBITDA
- 1.04
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -83.52%
- ROIC
- -82.30%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-61,079,000
- Net Income
- $-61,235,000-68.4%
- EPS
- $-1.45+62.5%
- OCF Growth
- -30.2%
- FCF Growth
- -29.5%
- 52W High
- $0.59
- 52W Low
- $0.30
- 50D MA
- $0.56
- 200D MA
- $0.49
- Beta
- -0.74
- RSI (14)
- 57
- Avg Volume
- 52.47K
No earnings-call transcripts are available for MTCR yet.
of shares held by institutions
27 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Pa Capital LLC | 34.28K | ▲ 34.28K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 23, 23 | Klassen Preston | other | 842,211 |
| Mar 23, 23 | Klassen Preston | sell | 842,211 |
| Jan 26, 23 | York Michael | sell | 107,054 |
| Jan 26, 23 | Klassen Preston | sell | 380,605 |
| Dec 21, 22 | Leonard Braden Michael | buy | 120,099 |
| Dec 20, 22 | Leonard Braden Michael | buy | 50,122 |
| Dec 19, 22 | Leonard Braden Michael | buy | 101,384 |
| Nov 9, 22 | Leonard Braden Michael | buy | 39,816 |
| Nov 8, 22 | Leonard Braden Michael | buy | 500 |
| Nov 7, 22 | Leonard Braden Michael | buy | 123,954 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MTCR coverage
Recent articles, reports, and earnings notes.
No research on MTCR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MTCR report →Trading Penny Stocks Under $1: Strategies for Succes & 7 To Watch
pennystocks.com · Dec 26
Metacrine: Potential Play On A Higher Bid
seekingalpha.com · Dec 15
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LOTZ, ECOM, MTCR, MNRL
prnewswire.com · Oct 6
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EQ, MTCR, STOR, RCKT
prnewswire.com · Sep 26
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ECOM, SGFY, EQ, MTCR
prnewswire.com · Sep 19
Metacrine To Slash Its Workforce By 50%
benzinga.com · Feb 11
Is the Options Market Predicting a Spike in Metacrine (MTCR) Stock?
zacks.com · Dec 20
3 Penny Stocks To Watch After Jerome Powell's Fed Announcement
pennystocks.com · Dec 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.